Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients Does not Prevent Infective Complications and Infections-related Deaths
Related Experiment Video
Updated: May 28, 2025

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Davide Leardini1, Giacomo Gambuti1, Edoardo Muratore1
1Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Insights
Levofloxacin prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HCT) did not reduce infections but increased quinolone-resistant strains. Gut microbiota was altered, with lower beneficial bacteria abundance in patients receiving prophylaxis.
Area of Science:
- Hematology
- Infectious Diseases
- Microbiology
Background:
- The use of quinolones for infection prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HCT) is debated, with limited evidence, especially in pediatric patients.
- This study addresses the controversy by evaluating levofloxacin prophylaxis in allo-HCT recipients.
Purpose of the Study:
- To compare outcomes between patients receiving and not receiving levofloxacin (LVX) prophylaxis after allo-HCT.
- To assess the impact of LVX prophylaxis on survival, graft-versus-host disease (GvHD), bloodstream infections, and gut microbiota composition.
Main Methods:
- A single-center retrospective study analyzed 144 allo-HCT procedures in 143 patients.
- Outcomes including overall survival, event-free survival, acute GvHD (aGvHD), and bloodstream infections were compared between patients receiving (n=74) or not receiving (n=70) LVX prophylaxis.
- Gut microbiota composition was analyzed using 16S rRNA sequencing in a subgroup of 50 patients.
Main Results:
- No significant differences were observed in key allo-HCT outcomes such as cumulative incidence of aGvHD, grade III-IV aGvHD, gut aGvHD, or bloodstream infections between the two groups.
- Patients receiving LVX prophylaxis exhibited a higher incidence of quinolone-resistant bacterial strains (P = .001).
- In the subgroup analysis, LVX prophylaxis was associated with a lower abundance of Blautia (P = .015), Enterococcus (P = .011), and Actinomyces (P = .07) at neutrophil engraftment.
Conclusions:
- Levofloxacin prophylaxis in the context of allo-HCT does not appear to prevent infectious complications.
- Prophylactic levofloxacin use is associated with an increased prevalence of antibiotic-resistant bacterial strains.
- LVX prophylaxis significantly alters gut microbiota composition, reducing the abundance of certain beneficial bacteria.
Background:
The prophylactic use of quinolones in the setting of allogeneic hematopoietic stem cell transplantation (allo-HCT) is controversial and solid evidence is missing, particularly in children.
Methods:
In this single-center retrospective study, we compared outcomes in patients receiving (n = 74) or not receiving (n = 70) levofloxacin (LVX) prophylaxis, assessing overall survival, event-free survival, acute graft-versus-host disease (aGvHD) and bloodstream infection incidence, and infection-related mortality. Gut microbiota composition was analyzed in a subgroup using 16S rRNA sequencing of stool samples collected pre-HCT and at engraftment.
Results:
We analyzed 144 allo-HCT in 143 patients performed for any indication. No differences were found in the 2 groups regarding main HCT outcomes, namely, cumulative incidence of aGvHD (37.9% vs 43.5%; P = .733), grade III-IV aGvHD (12.2% vs 8.7%; P = .469), gut aGVHD (12.2% vs 17.5%; P = .451), bloodstream infections (25.6% vs 34.1%; P = .236) and death from bacterial infection (9.5% vs 4.3%; P = 0.179). In patients experiencing bacterial infections, those receiving prophylaxis showed higher incidence of quinolone-resistant strains (P = .001). On a subgroup of 50 patients, we analyzed the gut microbiota composition, showing a lower abundance of Blautia (P = .015), Enterococcus (P = .011), and Actinomyces (P = .07) at neutrophil engraftment in patients receiving LVX prophylaxis.
Conclusions:
LVX prophylaxis in the setting of allo-HCT does not prevent infective complications and increases the prevalence of antibiotic-resistant strains.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
03:40Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Regulation of Hematopoietic Stem Cells